Bristol Myers Squibb disclosed that a confirmatory study for Krazati failed in colorectal cancer, providing an update on the drug’s evidence package. The company said patients taking Krazati in combination with an EGFR inhibitor did not meet the confirmatory trial’s intended outcome in the colorectal setting. The filing is significant because confirmatory trials can determine whether regulators expand label scope or whether post-approval expectations tighten. For the broader oncology market, Krazati’s trajectory also affects competitive positioning among KRAS-pathway and EGFR-combination strategies in solid tumors. BMS’s update adds near-term uncertainty for planned development steps and reinforces how quickly sponsor plans can shift after confirmatory failures.